A team with a shared passion for genetics and health prevention

Arndt is a Professor at the University of Rostock, Germany, multi-entrepreneur in biotech, founder and former CEO of CENTOGENE. He received his MD in 1985 and was granted a tenure track professorship for clinical neurology in 1997 at the University of Rostock. In 2008, Arndt was appointed Director of the Albrecht-Kossel-Institute for Neuroregeneration at the University of Rostock. Arndt has initiated multiple international multicenter studies in genetic disorders with an extensive track record in medical and scientific publications.

Michael has worked in the pharmaceutical and biotech industries for 30+ years, with 25+ years as a CEO, business angel and investor in fast-growing biotech, pharma and IT companies. Michael has lived and worked all over the world and in more than 10 countries for companies including Sandoz/Novartis, Abbott, ProBioGen AG and the NASDAQ-listed CENTOGENE. He is highly experienced in building up and reorganising start-ups and technology companies. Today, he is head of the supervisory board of the IT company OXID eSales AG in Freiburg as well as supervisory member of the MBA Programme at the University of Potsdam.

Michael founded Arcensus together with Arndt at the end of 2020.

Michael studied Business in Hamburg and completed an MBA Programme in the UK with the assistance of a BAT scholarship.

Christine has worked for 20+ years as a finance executive in fast-growing, innovative and international IT and life science businesses.

She has extensive experience in finance and controlling in internationally active, innovative and, above all, growing companies. Christine holds a degree in Business Economics and was most recently CFO at CENTOGENE, a global diagnostics company. There, she was responsible for developing the company's financial architecture and expansion strategy and successfully supported growth corresponding to more than a tenfold increase in sales within five years. Furthermore, she has held several management positions in biotechnology and technology companies, including curasan AG, ProBioGen AG, OD-OS GmbH, SPM Technologies GmbH and SAP Systems Integration AG.

Gabriela holds a PhD in Natural Science from University of Cologne, Germany and has been an active researcher in Human Genetics for almost 15 years. Her discovery and characterisation of the first protective modifier of autosomal recessive spinal muscular atrophy [Science, 2008] gained her several awards. She is a highly motivated and experienced scientist in analysis, interpretation and utilisation of genetic information within clinical context, efficiently turning big data into knowledge-based products. She acted as SVP Genetic Data Processing and Digital Products for a 7+ years at CENTOGENE, where she contributed to the successful optimisation and automation of genetic diagnostic and curation related processes. She had the opportunity to get in-depth exposure to big-data analysis and patterns discovery, along with successful proof-of-concept of AI application in variant classification, clinical statement generation and reporting. In 2020, Gabriela was appointed as General Director at Personal Genetics (Bucharest, Romania) where she remarkably implemented the next generation sequencing technology and methodology in house. Finding creative ideas how to improve and optimise „things”, drives her every day.

Sebastian has been working within the technology and start-up ecosystem in Europe and the US for 10+ years. With his in-depth experience in the fields of consumer products, B2B SaaS and Deep Tech (automation technology and AI), he has a holistic understanding of business building and operations. As a founder, operator and mentor for various technology start-ups in the field of B2C and B2B, he brings expansive leadership and digital product experience to Arcensus. Sebastian is an entrepreneurial professional with a bachelor‘s degree in International Management and a master‘s degree in Organisational Innovation & Entrepreneurship from Copenhagen Business School, as well as an early OnDeck Fellow.

Volha is a strong leader, highly motivated and dedicated to all partners. She started her career during her bachelor’s thesis at the Republican Theoretical and Practical Center – ‘Mother and Child’ in Minsk, Belarus. Afterward, she investigated the translational regulation of the innate immune response in tuberculosis infection during her master’s thesis at the Max Planck Institute in Berlin, Germany. She has completed her PhD thesis on the host fungal micronutrient interaction at the Hans Knoell Institute in Jena, Germany in 2018. Until early 2021, Volha has worked as a Director of Clinical Studies at CENTOGENE. She executed plenty of observational clinical studies worldwide to analyse the prevalence of rare diseases allowing patients to be diagnosed at the earliest possible moment. Additionally, she performed longitudinal observational clinical studies to validate and monitor biomarkers required for diagnosis and treatment personalisation.